HLA
KYNB

Hamilton Lane Advisors’s Kyntra Bio KYNB Stock Holding History

Hamilton Lane Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-712
Closed -$390K – 52
2015
Q3 		$390K Sell
712
-9,562
-93% -$5.79M 0.19% 45
2015
Q2 		$6.04M Buy
+10,274
New +$5.98M 2.28% 16

Other funds holding KYNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hamilton Lane Advisors's KYNB Position: Q4 2015 in Review

Hamilton Lane Advisors sold out of Kyntra Bio (KYNB) in Q4 2015, closing a stake of 712 shares — an estimated $390K sold.

Hamilton Lane Advisors first reported a position in KYNB in Q2 2015 and held it in 2 quarters. The position peaked at $6.04M in Q2 2015. 134 funds tracked by Wall St. Rank hold KYNB as of Q4 2015.

  • Hamilton Lane Advisors reported no remaining Kyntra Bio position as of Q4 2015 after selling out during the quarter.
  • Hamilton Lane Advisors sold 712 Kyntra Bio shares in Q4 2015, an estimated $390K.
  • Hamilton Lane Advisors first reported a position in Kyntra Bio in Q2 2015 and held it in 2 quarters.
  • Hamilton Lane Advisors's Kyntra Bio position peaked at $6.04M in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2015.

Based on Hamilton Lane Advisors's 13F filing for Q4 2015, filed 22 Jan 2016.